Publications
Fox SC et al (2019). How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy? Platelets, 30(3): 290-295.
Bath P et al (2018). Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets, 29(5): 425-430.
Germanovich et al (2015). Comparison of the Biocytex and the VASPFix assays of VASP phosphorylation in coronary-artery disease patients treated with clopidogrel plus aspirin.
onlinelibrary.wiley.com – page 784
Afghani M et al (2015). A new approach to measuring platelet aggregation and platelet-leucocyte conjugate formation in a small volume of fixed whole blood.
onlinelibrary.wiley.com – page 655
Fox SC et al (2013). Effects on platelet function of an EP3 receptor antagonist used alone and in combination with P2Y12 antagonist both in vitro and ex vivo in human volunteers. Platelets, 24(5): 392-400.
Thomas M et al (2014). A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. Platelets, 25(8), pp.612-618.
Glenn JR et al (2014). ‘VASPFix’ for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists. Thromb Haemost, 111(3): 539-548.
DOI: 10.1160/TH13-07-0581
Lordkipanidze MD et al (2013). Development of a novel high throughput 96 well plate-based whole blood assay for investigation of platelet function in healthy volunteers and patients with clinically diagnosed bleeding disorders.
onlinelibrary.wiley.com – page 763
Iyú D et al (2011). P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets, 22(7): 504-515.
Manolopoulos P et al (2008). Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: A new finding that may influence the design of anti-thrombotic agents. Platelets, 19(2): 134-145.
Heptinstall S et al (2008). DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease. Platelets, 19(8): 605-613.
Husted S et al (2006). Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European Heart Journal, 27(9): 1038-1047.
Van Giezen JJJ and Humphries RG (2005). Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. In Seminars in thrombosis and hemostasis, 31(2): 195-204.
Zhao L et al (2003). The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Current Medical Research and Opinion, 19(3): 178-186.
Zhao L et al (2001). Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. British Journal of Pharmacology, 134(2): 353-358.
Jarvis GE et al (2000). ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. British Journal of Pharmacology, 129(2): 275-282.
Humphries RG et al (1994). FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T‐purinoceptors. British Journal of Pharmacology, 113(3): 1057-1063.
